Pharmaceuticals News

‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per...

L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil  La...

A new therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens for sleeping sickness.

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016,...

ORION OYJ        PÖRSSITIEDOTE – TILINPÄÄTÖS JA TOIMINTAKERTOMUS        27.2.2026 KLO 11.05         Orion-konsernin tilinpäätösasiakirjat 2025 sekä palkitsemisraportti julkaistu ...

ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 27 FEBRUARY 2026 at 11.05 EET         Orion Group Financial Statement documents 2025 and Remuneration Report published Orion...

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Pratteln, Schweiz, 27. Februar 2026 – Santhera Pharmaceuticals (SIX: SANN) gibt heute bekannt, dass die spanische interministerielle Kommission für Arzneimittelpreise vorgeschlagen hat, AGAMREE®...

Pratteln, Switzerland, February 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE®...

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and...